Sogroya Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Somapacitan

Indications/Uses

Replacement of endogenous growth hormone (GH) in childn ≥3 yr & adolescents w/ growth failure due to growth hormone deficiency (paed GHD), & in adults w/ growth hormone deficiency (adult GHD).

Dosage/Direction for Use

SC Paed GHD Treatment-naïve paed patient & paed patient switching from other GH medicinal products Initially 0.16 mg/kg/wk. Adult GHD Naïve patient Adult ≥18 to <60 yr Initially 1.5 mg/wk. Women on oral oestrogen therapy (irrespective of age) Initially 2 mg/wk. Elderly ≥60 yr Initially 1 mg/wk. Patient switching from daily GH medicinal products Adult ≥18 to <60 yr Initially 2 mg/wk. Women on oral oestrogen therapy (irrespective of age) Initially 4 mg/wk. Elderly ≥60 yr Initially 1.5 mg/wk.

Contraindications

Hypersensitivity. Not to be used when there is any evidence of activity of a tumour. Discontinue treatment if there is evidence of tumour growth. Patients w/ acute critical illness suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute resp failure or similar conditions. Not to be used for longitudinal growth promotion in childn w/ closed epiphyses.

MIMS Class

Trophic Hormones & Related Synthetic Drugs

ATC Classification

H01AC07 - somapacitan ; Belongs to the class of somatropin and somatropin agonists. Used in anterior pituitary lobe hormone and analogue preparations.

Regulatory Classification

POM

Presentation/Packing

Form

Sogroya soln for inj 10 mg/1.5 mL

Packing/Price

(pre-filled pen) 1's

Form

Sogroya soln for inj 15 mg/1.5 mL

Packing/Price

(pre-filled pen) 1's

Form

Sogroya soln for inj 5 mg/1.5 mL

Packing/Price

(pre-filled pen) 1's

Sogroya

Manufacturer:

Novo Nordisk A/S